Haselmeier GmbH Announces the Launch Of INSUPen® EZ In India By BioCon Limited

Zurich, Switzerland, October 27, 2014 / B3C newswire / – Haselmeier announces that Biocon, one of Asia’s premier biotechnology companies, has just launched INSUPen® EZ in India. The INSUPen® EZ is a second generation pen and follows on the success of Biocon’s premier insulin delivery device INSUPen®. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen® EZ, for use with Biocon’s insulin, Basalog™ and Insugen™, and insulin analogues.

The INSUPen® EZ is a reusable insulin pen, based on Haselmeier’s new i-pen² platform and is designed to be easy to use and provide a smoother injection experience. It can deliver insulin doses from 1 unit (0.01 ml) to 60 units (0.60 ml) in increments of 1 unit (0.01 ml) with insulin preparations of 100 IU/ml and features an audible sound when dialling a dose for accurate and reliable dosing. The INSUPen® EZ is available in an egg shell white thermo-resistant, light-weight Terluran body and is available in different colours for differentiating insulins.

The launch of INSUPen® EZ, represents another milestone in the long-standing relationship between Biocon and Haselmeier. “Haselmeier is delighted to collaborate with Biocon and contribute to the market introduction of INSUPen® EZ”, says Sandra de Haan, Director Project Management at Haselmeier GmbH.

About Haselmeier

Founded in Stuttgart in 1920, Haselmeier is one of the leading designers and manufacturers of injection systems. Haselmeier’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. At five locations on three continents, Haselmeier develops and produces innovative technology for drug delivery which enhances the health and daily life of the patient.

About Biocon

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).

Contact:
Nadia Di Secli
Marketing Manager
Haselmeier GmbH
Dufourstrasse 32
8008 Zürich
Switzerland
Tel: +41 44 250 58 50
n.secli@haselmeier.com

Help employers find you! Check out all the jobs and post your resume.